Literature DB >> 33063442

Mus musculus papillomavirus 1 is a key driver of skin cancer development upon immunosuppression.

Sonja Dorfer1, Katharina Strasser1, Georg Schröckenfuchs1, Michael Bonelli2, Wolfgang Bauer1, Harald Kittler1, Christophe Cataisson3, Michael B Fischer4, Beate M Lichtenberger1, Alessandra Handisurya1.   

Abstract

Epidemiological and experimental data implicate cutaneous human papillomavirus infection as co-factor in the development of cutaneous squamous cell carcinomas (cSCCs), particularly in immunocompromised organ transplant recipients (OTRs). Herein, we established and characterized a skin cancer model, in which Mus musculus papillomavirus 1 (MmuPV1) infection caused cSCCs in cyclosporine A (CsA)-treated mice, even in the absence of UV light. Development of cSCCs and their precursors were observed in 70% of MmuPV1-infected, CsA-treated mice on back as well as on tail skin. Immunosuppression by systemic CsA, but not UV-B irradiation, was a prerequisite, as immunocompetent or UV-B-irradiated mice did not develop skin malignancies after infection. In the virus-driven cSCCs the MmuPV1-E6/E7 oncogenes were abundantly expressed, and transcriptional activity and productive infection demonstrated. MmuPV1 infection induced the expression of phosphorylated H2AX, but not degradation of proapoptotic BAK in the cSCCs. Transfer of primary cells, established from a MmuPV1-induced cSCC from back skin, into athymic nude mice gave rise to secondary cSCCs, which lacked viral DNA, demonstrating that maintenance of the malignant phenotype was virus independent. This papillomavirus-induced skin cancer model opens future investigations into viral involvement, pathogenesis, and cancer surveillance, aiming at understanding and controlling the high incidence of skin cancer in OTRs.
© 2020 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  animal models: murine; basic (laboratory) research / science; cancer / malignancy / neoplasia: skin - nonmelanoma; dermatology; immunosuppressant - calcineurin inhibitor: cyclosporine A (CsA); immunosuppression / immune modulation; infection and infectious agents - viral; infectious disease

Mesh:

Year:  2020        PMID: 33063442      PMCID: PMC7894140          DOI: 10.1111/ajt.16358

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  42 in total

Review 1.  Beta genus papillomaviruses and skin cancer.

Authors:  Peter M Howley; Herbert J Pfister
Journal:  Virology       Date:  2015-02-24       Impact factor: 3.616

2.  The presence of betapapillomavirus antibodies around transplantation predicts the development of keratinocyte carcinoma in organ transplant recipients: a cohort study.

Authors:  Roel E Genders; Hadi Mazlom; Angelika Michel; Elsemieke I Plasmeijer; Koen D Quint; Michael Pawlita; Els van der Meijden; Tim Waterboer; Hans de Fijter; Frans H Claas; Ron Wolterbeek; Mariet C W Feltkamp; Jan Nico Bouwes Bavinck
Journal:  J Invest Dermatol       Date:  2014-10-27       Impact factor: 8.551

Review 3.  Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.

Authors:  Kate Connolly; Pete Manders; Peter Earls; Richard J Epstein
Journal:  Cancer Treat Rev       Date:  2013-08-22       Impact factor: 12.111

Review 4.  Germinal Center B Cell Dynamics.

Authors:  Luka Mesin; Jonatan Ersching; Gabriel D Victora
Journal:  Immunity       Date:  2016-09-20       Impact factor: 31.745

5.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

Authors:  Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger Kjaer; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

6.  E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation.

Authors:  Michael P Underbrink; Heather L Howie; Kristin M Bedard; Jennifer I Koop; Denise A Galloway
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

Review 7.  Development of a β-HPV vaccine: Updates on an emerging frontier of skin cancer prevention.

Authors:  Rohit Gupta; Peter L Rady; Hung Q Doan; Stephen K Tyring
Journal:  J Clin Virol       Date:  2020-04-04       Impact factor: 3.168

8.  Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis.

Authors:  Scott J Roberts; Bernice Y Ng; Renata B Filler; Julia Lewis; Earl J Glusac; Adrian C Hayday; Robert E Tigelaar; Michael Girardi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-05       Impact factor: 11.205

9.  Immune status, strain background, and anatomic site of inoculation affect mouse papillomavirus (MmuPV1) induction of exophytic papillomas or endophytic trichoblastomas.

Authors:  John P Sundberg; Timothy M Stearns; Joongho Joh; Mary Proctor; Arvind Ingle; Kathleen A Silva; Soheil S Dadras; A Bennett Jenson; Shin-je Ghim
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

10.  The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer.

Authors:  Michael Girardi; Earl Glusac; Renata B Filler; Scott J Roberts; Iva Propperova; Julia Lewis; Robert E Tigelaar; Adrian C Hayday
Journal:  J Exp Med       Date:  2003-09-01       Impact factor: 14.307

View more
  2 in total

1.  Expanded Basal Compartment and Disrupted Barrier in Vocal Fold Epithelium Infected with Mouse Papillomavirus MmuPV1.

Authors:  Renee E King; Ella T Ward-Shaw; Rong Hu; Paul F Lambert; Susan L Thibeault
Journal:  Viruses       Date:  2022-05-16       Impact factor: 5.818

2.  A novel lineage-tracing mouse model for studying early MmuPV1 infections.

Authors:  Vural Yilmaz; Panayiota Louca; Louiza Potamiti; Mihalis Panayiotidis; Katerina Strati
Journal:  Elife       Date:  2022-05-09       Impact factor: 8.713

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.